Intellia Therapeutics Stock News

CAMBRIDGE, Mass., and GALWAY, Ireland and SAN DIEGO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapies leveraging CRISPR-based technologies, and ONK Therapeutics Ltd., an innovative company dedicated to developing optimally engineered natural killer (NK) cell therapies to cure patients with cancer, today announced a licensing and collaboration agreement. NK cells are specialized, naturally occurring immune cells that play a critical role in immune activation against abnormal cells, including cancer cells. NK cells have gained significant attention in the field of cancer immunotherapy and various approaches are being explored to effectively develop and engineer NK cell-based cancer immunotherapy.

Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40, compared to $0.09 from the yea

Upgrades For Enova International Inc (NYSE:ENVA), Maxim Group upgraded the previous rating of Hold to Buy. For the fourth quarter, Enova International had an EPS of $1.61, compared to year-ago quarter

Upgrades For Enova International Inc (NYSE: ENVA ), Maxim Group upgraded the previous rating of Hold to Buy. For the fourth quarter, Enova International had an EPS of $1.61, compared to year-ago quarter EPS of $2.39. The current stock performance of Enova International shows a 52-week-high of $44.43 and a 52-week-low of $23.88. Moreover, at the end of the last trading period, the closing price was at $41.22. Argus Research upgraded the previous rating for Nasdaq Inc (NASDAQ: NDAQ ) from Hold to Buy. For the fourth quarter, Nasdaq had an EPS of $1.93, compared to year-ago quarter EPS of $1.60. The current stock performance of Nasdaq shows a 52-week-high of $214.96 and a 52-week-low of $135.57. Moreover, at the end of the last trading period, the closing price was at $178.62. Argus Research upgraded the previous rating for The Hershey Co (NYSE: HSY ) from Hold to Buy. Hershey earned $1.69 in the fourth quarter, compared to $1.49 in the year-ago quarter. The stock has a 52-week-high of $206.16 and a 52-week-low of $143.58.

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC.

Intellia Therapeutics (NTLA) acquired Rewrite Therapeutics, a biotechnology firm focused on advancing novel DNA writing technologies.NTLA will pay Rewrite shareholders $45M in an

CAMBRIDGE, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging

Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago quarter EPS of $2.25.

And a look at market news including Netflix shares falling more than 20% as increasing competition cuts into subscriber growth.

They've taken a beating, but the industries they track are still growing.

The recent market dip offers an attractive entry point for a speculative trade on gene-editing tech.

Intellia is considered the best gene editing company because of its first mover status in the use of in vivo gene editing technology.

Andreas Halvorsen (Trades, Portfolio), chief investment officer of Viking Global Investors, disclosed a stake in Amylyx Pharmaceuticals Inc. ( AMLX , Financial) late last week.